BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kruse NT. Nutraceuticals as a potential adjunct therapy toward improving vascular health in CKD. Am J Physiol Regul Integr Comp Physiol 2019;317:R719-32. [PMID: 31577157 DOI: 10.1152/ajpregu.00152.2019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Sachinidis AG, Nikolic D, Stoian AP, Toth PP, Rizzo M. Nutraceuticals and Lipid Management. In: Davidson MH, Toth PP, Maki KC, editors. Therapeutic Lipidology. Cham: Springer International Publishing; 2021. pp. 173-89. [DOI: 10.1007/978-3-030-56514-5_10] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Wu Q, Wang J, Wang Y, Xiang L, Tan Y, Feng J, Zhang Z, Zhang L. Targeted delivery of celastrol to glomerular endothelium and podocytes for chronic kidney disease treatment. Nano Res 2021;:1-13. [PMID: 34925707 DOI: 10.1007/s12274-021-3894-x] [Reference Citation Analysis]
3 Samson WK, Carter JR, Yosten GLC. The 2019 New Investigator Review Award Announcement. Am J Physiol Regul Integr Comp Physiol 2020;318:R189-90. [PMID: 31899670 DOI: 10.1152/ajpregu.00362.2019] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Su X, Zhou M, Li Y, Zhang J, An N, Yang F, Zhang G, Yuan C, Chen H, Wu H, Xing Y. Protective effects of natural products against myocardial ischemia/reperfusion: Mitochondria-targeted therapeutics. Biomed Pharmacother 2022;149:112893. [PMID: 35366532 DOI: 10.1016/j.biopha.2022.112893] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
5 Rysz J, Franczyk B, Kujawski K, Sacewicz-Hofman I, Ciałkowska-Rysz A, Gluba-Brzózka A. Are Nutraceuticals Beneficial in Chronic Kidney Disease? Pharmaceutics 2021;13:231. [PMID: 33562154 DOI: 10.3390/pharmaceutics13020231] [Reference Citation Analysis]